AUSTIN, Texas - Natera Inc. (NASDAQ:NTRA) announced the appointment of Thomas Lynch and Eric Rubin to its board of directors, according to a press release statement issued today. The appointments come as the company, valued at $30.5 billion, continues to expand its oncology capabilities with revenue reaching $2.5 billion over the last twelve months and growing 37% year-over-year.
Lynch serves as President and Director of Fred Hutch Cancer Center and holds the Raisbeck Endowed Chair. He has more than 30 years of experience at cancer centers and previously held positions including Chief Scientific Officer at Bristol-Myers Squibb, CEO of Massachusetts General Physicians Organization, and director of Yale Cancer Center.
Rubin brings over 35 years of experience in cancer drug development. He most recently served as senior vice president of global clinical oncology at Merck, where he worked for 16 years and led the initial development of pembrolizumab, the first anti-PD-1 therapy approved in the United States. He previously held faculty positions at Dana-Farber Cancer Institute and served as director of the investigational therapeutics division at Rutgers Cancer Institute of New Jersey. Rubin has authored more than 100 peer-reviewed publications.
Lynch has joined the company’s Human Capital Committee, while Rubin has joined the Nominating, Corporate Governance and Compliance Committee.
Natera develops cell-free DNA testing and diagnostics focused on oncology, women’s health, and organ health. The company operates laboratories in Austin, Texas, San Carlos, California, and Boulder, Colorado through its subsidiary Foresight Diagnostics. According to InvestingPro analysis, 7 analysts have revised their earnings upwards for the upcoming period, though the platform’s Fair Value suggests the stock may be overvalued at current levels.
In other recent news, Natera Inc. has been the focus of several significant developments. Wolfe Research initiated coverage on Natera with an outperform rating and set a price target of $260. This assessment is based on a long-term discounted cash flow model, highlighting Natera’s market leadership in molecular residual disease testing. Additionally, Natera has partnered with Diakonos Oncology Corp. to evaluate molecular responses in refractory melanoma patients using its Signatera test in a Phase I/II trial.
Natera also announced an enhancement to its Panorama non-invasive prenatal test, reducing the no-call rate to 0.5% by utilizing SNP-informed deep sequencing technology. The company plans to present 35 oncology abstracts at the 2026 American Society of Clinical Oncology Annual Meeting, focusing on molecular residual disease testing. Furthermore, Natera is expanding its North Austin headquarters, which includes a new sequencing facility and additional laboratory space, expected to boast the largest sequencing capacity globally. These recent developments reflect Natera’s ongoing efforts to strengthen its technological capabilities and market presence.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.
Most traders can read a chart. The hard part is the moment: entry window open, pattern forming, and you're still waiting for more confirmation. That's the conviction gap — and our chart analysis closes it. Unlike other AIs that just read data, our Vision AI literally "sees" your charts and hands you a complete trading plan: entry, stop-loss, and profit target in under 60 seconds. Know exactly what to do next, every time.